Welcome!

In partnership with the CHEST Delegation Italy
Virchow's Triad and the Perfect Storm: VTE in Patients With COVID-19

Lisa K Moores MD, FCCP, MACP, FRCP

Associate Dean for Assessment and Professional Development
Professor of Medicine
F. Edward Hebert School of Medicine
Uniformed Services University of the Health Sciences
Bethesda, MD
Disclosures

• No financial, intellectual or research conflicts of interests to disclose
A. Thrombosis of mid-sized pulmonary artery

B. Thrombosis of small-sized pulmonary artery (infiltrated by neutrophils)

C. Pulmonary artery with thrombosis and infarction with PNA of surrounding lung tissue

D. Microthrombi of small arteries in areas of diffuse alveolar damage
CHEST Guideline

- Expert panel
- PICO development
- Systematic review
- GRADE
- Existing guidance
- Delphi process

Authors
Lisa K. Moores MD
Tobias Tritschler MD, MSc
Shari Brosnahan MD
Marc Carrier MD
Jacob F. Collen MD
Kevin Doerschug MD, MS
Aaron B. Holley MD
David Jimenez MD, PhD
Gregoire Le Gal MD, PhD
Parth Rali MD
Philip Wells MD

Main Statements

• All acutely hospitalized patients with COVID-19 should receive thromboprophylaxis
• LKMWH or fondaparinux over UFH and DOACs
• Insufficient data to justify routine increased intensity
Main Statements

• Inpatient only thromboprophylaxis
• In ICU COVID-19 patients, suggest against routine ultrasound screening
• For ICU COVID-19 patients with proximal DVT or PE, recommend parenteral therapy with LMWH
# Ongoing RCTs evaluating thromboprophylaxis

<table>
<thead>
<tr>
<th>Study name or PI</th>
<th>Intervention</th>
<th>Study name or PI</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-HEP</td>
<td>Therapeutic LMWH or UFH</td>
<td>COVI-DOSE</td>
<td>Therapeutic LMWH</td>
</tr>
<tr>
<td>CORIMMUNO-COAG</td>
<td>Therapeutic LMWH or UFH</td>
<td>Albaghdadi</td>
<td>Therapeutic LMWH or UFH</td>
</tr>
<tr>
<td>ACOVACT</td>
<td>Rivaroxaban 5 mg BID</td>
<td>Heparin-SARS-CoV2</td>
<td>Intermediate-dose LMWH</td>
</tr>
<tr>
<td>Perepu</td>
<td>Intermediate-dose LMWH</td>
<td>HeSAcovid</td>
<td>Therapeutic LMWH or UFH</td>
</tr>
<tr>
<td>REMAP-COVID</td>
<td>Therapeutic LMWH or UFH</td>
<td>COALIZAZO ACTION</td>
<td>Therapeutic AC</td>
</tr>
<tr>
<td>Berger</td>
<td>Therapeutic LMWH or UFH</td>
<td>HEP-COVID</td>
<td>Therapeutic LMWH</td>
</tr>
<tr>
<td>RAPID COVID COAG</td>
<td>Therapeutic LMWH or UFH</td>
<td>IMPACT</td>
<td>Therapeutic AC</td>
</tr>
<tr>
<td>X-Covid 19</td>
<td>Intermediate-dose LMWH</td>
<td>COVID-19 HD</td>
<td>Therapeutic LMWH</td>
</tr>
<tr>
<td>ATTACC</td>
<td>Therapeutic LMWH or UFH</td>
<td>COVID PACT</td>
<td>Therapeutic LMWH or UFH ±clopidogrel</td>
</tr>
<tr>
<td>IMPROVE-COVID</td>
<td>Intermediate-dose LMWH or UFH</td>
<td>COVID-PREVENT</td>
<td>Therapeutic rivaroxaban</td>
</tr>
</tbody>
</table>
What are your questions?